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To date, topical therapies guarantee a better delivery of high concentrations of pharmacologic agents to the mucosa of the upper
airways (UA). Recently, topical administration of ectoine has just been recognized as adjuvant treatment in the Allergic Rhinitis
(AR) and Rhinosinusitis (ARS). The aim of this work is to review the published literature regarding all the potential therapeutic
effects of ectoine in the acute and chronic inflammatory diseases of UA. Pertinent studies published without temporal limitation
were selected searching on MEDLINE the following terms: “ectoine” and “nasal spray,” “oral spray,” “upper respiratory tract
infections,” “rhinosinusitis,” “rhinitis,” “rhinoconjunctivitis,” “pharyngitis,” and “laryngitis.” At the end of our selection process,
six relevant publications were included: two studies about the effect of ectoine on AR, one study about ARS, one study about rhinitis
sicca anterior, and two studies about acute pharyngitis and/or laryngitis. Due to its moisturizing and anti-inflammatory properties,
topical administration of ectoine could play a potential additional role in treatment of acute and chronic inflammatory diseases of
UA, in particular in the management of sinonasal conditions improving symptoms and endoscopic findings. However, these results
should be viewed cautiously as they are based on a limited number of studies; some of them were probably underpowered because
of their small patient samples.
1. Introduction
Ectoine is a low-molecular, cyclic tetrahydropyrimidine or-
ganic osmolyte, which was first identified by Galinski et al. [1]
in the halophilic bacterium, Ectothiorhodospira halochloris,
but since then it has been found in other extremophiles
microorganisms. To protect themselves from external stress
factors such as extreme temperatures, high salt concentra-
tions, and ultraviolet radiations, these microorganisms pro-
duce stress-protection molecules, also called extremolytes.
Among these molecules, there is ectoine [2]. It is known
that ectoine works via an entropy-driven mechanism called
“preferential exclusion” or “preferential hydration” during
which ectoine influences the characteristics of the “water
shell” surrounding biomolecules like membranes. By exclud-
ing osmolytes from the direct hydrate shell of proteins and
membranes, a preferential hydration of such proteins or
membranes occurs, thereby stabilizing their native confirma-
tion and making them less vulnerable to external stressors.
As suggested by Yancey PH [3] and Arakawa T. et al. [4]
destabilizers molecules such as some salt ions and urea
generally bind to proteins, causing them to unfold because
this exposes more groups that undergo thermodynamically
favorable binding with the destabilizer. By contrast, many
stress-protection molecules such as ectoine do not bind to
proteins; indeed, they are excluded from a protein’s hydration
layer (the water molecules adjacent to a protein’s surface).
Because of this repulsion, proteins will tend to fold up
Hindawi
BioMed Research International
Volume 2019, Article ID 7150942, 10 pages
https://doi.org/10.1155/2019/7150942
2 BioMed Research International
more compactly, since this will reduce exposure of the
peptide-bond backbone to thermodynamically unfavorable
interactions with the stabilizing solute.
In addition to its moisturizing properties, it has been
shown that ectoine limits the inflammatory cascade at the
membrane level of respiratory and skin cells. In partic-
ular, patients’ pulmonary epithelium affected by Chronic
Obstructive Pulmonary Disease, ectoine is able to reduce the
neutrophilic inflammatory response induced by exposure to
environmental and occupational pollutants such as the car-
bon nanoparticles [5]. Although the precise mechanisms are
not completely clear, it seems that this molecule plays a sta-
bilizing role in receptor structures, effectively preventing the
signalling cascade [6]. Taken together, anti-inflammatory and
hydration properties make ectoine an interesting candidate
for application in diseases where cell membrane protection is
fundamental. Indeed, ectoine is widely used in dermatology
and neither contraindications nor interactions with drugs are
reported. Topical application of ectoine to lesional skin of
patients suffering from mild to moderate atopic dermatitis
significantly reduced the clinical severity of this disease [7].
Recently, topical administration of ectoine has also been
used for many inflammatory diseases’ treatment of the upper
airways (UA) such as Allergic Rhino Conjunctivitis (ARC),
Rhinitis Sicca Anterior, and Acute Pharyngitis. A 2014 meta-
analysis [8] concluded that the use of ectoine-based nasal
sprays improves symptoms of ARC with no side effects,
effectively reduces sinonasal symptoms, and represents an
exciting alternative in themanagement of ARC.However, this
paper included only three studies, two of them not published
before, without detailed information, excluding clinical trials
about the use of ectoine on other upper airways diseases.
The aim of this work is to review the published literature
regarding all the potential therapeutic effects of ectoine in
the acute and chronic inflammatory diseases of UA, trying to
investigate better the main application areas of ectoine, the
root and schedule of ectoine administration, and the main
efficacy parameters evaluation.
2. Methods
2.1. Search Strategy andArticle Selection Process. A searchwas
made of the PubMed, Google Scholar, and Ovid databases
according to the PRISMA guidelines [9] using the follow-
ing key words or in the case of PubMed medical subject
headings: “ectoine” and “nasal spray,” “ectoine” and “oral
spray,” “ectoine” and “upper respiratory tract infections,”
“ectoine” and “allergic rhinitis,” “ectoine” and “rhinosi-
nusitis,” “ectoine” and “rhinoconjunctivitis,” “ectoine” and
“rhinitis,” “ectoine” and “pharyngitis,” ectoine” and “laryn-
gitis.” Only studies in English, published in peer-reviewed
journals, reporting data on the role of the topical admin-
istration of ectoine in the UA are included; no studies
related to dentistry have been considered. Literature reviews,
technical notes, letters to editors, and instructional course
were excluded. Additional literature was found by reviewing
the reference lists of the selected articles. Hence, the authors
then independently assessed the full-text versions of each
publication and excluded thosewhose contentwas judged not
to be strictly related to the subject of this review.
At the end of our selection process, we included six
clinical studies which investigated the potential role of topical
ectoine in UA, involving 474 patients: two studies about
AR, one study about ARS, one study about rhinitis sicca
anterior, and two studies about acute pharyngitis and/or
laryngitis.
3. Results
The effects of these studies are summarized in Table 1.
3.1. Ectoine and Allergic Rhinitis. Sonnemann U et al. [10]
compared the effect of ectoine nasal spray with beclometha-
sone nasal spray on 50 patients with AR for 14 days. In par-
ticular, 25 patients used 2% ectoine nasal spray (three times
a day) while 25 patients used 0.05% beclomethasone nasal
spray (twice a day). During the treatment period, patients
and physicians evaluated total nasal symptom score (TNSS),
single symptoms score (nasal obstruction, rhinorrhea, nasal
itching, and sneezing), efficacy, and tolerability of both treat-
ments. Patients also completed a quality of life questionnaire.
At the end of the treatment, physician’s assessment of TNSS
showed a significant reduction from baseline in both groups
while patient’s assessment showed a significant reduction
only for beclomethasone group. The authors did not confirm
the noninferiority of ectoine compared to beclomethasone
nasal spray. Only from single symptoms patient’s analysis, a
significant reduction of sneezing in beclomethasone group
was recorded compared to ectoine group. There were not
any significant differences between both groups for patient’s
evaluation of quality of life, while in the physician’s evaluation
a significant improvement for the frequency of brushing
the nose in beclomethasone was observed compared to
ectoine group. Finally, patient and physicians judged the
tolerability of both products similarly (“good” to “very
good”) without differences. Efficacy assessed by patients and
physician significantly increased over the treatment period in
beclomethasone group compared to ectoine group.
Werkhauser N et al. [11] investigated the effects of ectoine
products in patients with AR in two studies. In the first trial,
48 patients were included: 22 received ectoine eye drops and
nasal spray (one eye drop and one puff of nasal spray four
times per day) and 26 patients received azelastine nasal spray
and eye drops (one eye drop and one puff of nasal spray twice
per day) for 7 days. Patients and physicians evaluated TNSS
(nasal obstruction, rhinorrhea, nasal itching, and sneezing)
and total ocular symptom score (TOSS) (conjunctivitis, eye
itching, and tearing), efficacy, and tolerability of both treat-
ments. Only physicians judged compliance. At the end of the
treatment, TNSS and TOSS evaluated by physicians showed a
significant reduction frombaseline in both groups. TNSS and
TOSS evaluated by patients decreased from baseline in both
groups without significant difference. Patients and physicians
assessments of efficacy and tolerability of both groups were
similar without significant difference. Compliance was good
in both groups, with no significant difference.
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In the second study, 50 patientswere included: 25 received
ectoine nasal spray (five times per day) whereas 25 received
cromoglycic acid nasal spray (four times a day). After 7 days,
patients swapped to the other treatment. During the follow-
up visits physicians and patients assessed TNSS, TOSS,
efficacy, and tolerably of both treatments. Compliance was
judged only by physicians. TNSS evaluated by physicians and
patients significantly decreased in both groups for all 14 days'
treatment. TOSS evaluated by patients significantly decreased
for all 14 days only in group with ectoine spray while TOSS
evaluated by physicians significantly improved for all 14 days
in both groups.
According to the physicians and patients judgment, the
efficacy of both treatments was rated “good to satisfactory”
without significant differences. Tolerability judged by physi-
cians and patients was significantly better following a 7-day
treatment with ectoine containing nasal spray in comparison
to cromoglycic acid product.The compliance was assessed as
very good by the physician, and values were not statistically
different between groups.
3.2. Ectoine and Acute Rhinosinusitis. Eichel A et al. [12]
compared the effects of 2% ectoine nasal spray to systemic
treatment with herbal formula, in 66 patients with ARS for
14 days. In particular, 48 patients received ectoine nasal spray
(one or two puffs into each nostril several times a day) and
18 patients received herbal phytotherapeutic dragées (one
dragéet three times a day). During the treatment, physicians
and patients recorded the Sinusitis Symptom Score (SSS)
and adverse events. In addition, physicians performed nasal
endoscopy and patients completed a sinusitis-specific health
related quality of life (HRQL) questionnaire. At the end of
the treatment, the SSS evaluated by physicians and patients
decreased significantly frombaseline during the study in both
groups (58.1% in ectoine group and 53.5% in control group)
without significant differences. Nasal endoscopy and HRQL
questionnaire scores improved from baseline in both groups
but significant difference was recorded only in ectoine group.
No adverse effects have been reported.
3.3. Ectoine and Rhinitis Sicca. Sonnemann U et al. [13]
evaluated the efficacy of ectoine nasal spray in patients with
rhinitis sicca in two studies. In the first clinical trial, 50
patients used 0.5% ectoine nasal spray while in the second
trial 30 patients used nasal spray containing 0.5% ectoine
with 1.0% dexpanthenol. No control groups were expected.
Patients and physicians assessed the main symptoms such
as nasal obstruction and crusting of the nose and secondary
symptoms such as endonasal blood deposits, concomitant
pharyngitis, cacosmia, rhinorrhea, exudate viscosity, and
turbinate hyperplasia. In addition, they judged efficacy and
tolerability of both products. After 14-day treatment, nasal
obstruction and nasal crust formations evaluated by physi-
cians and patients improved significantly in both trials.
Secondary symptoms evaluated by physicians significantly
improved over the time in both studies, with the exception
of rhinorrhea, which improved significantly only in the
second study. From the analysis of the secondary symptoms
conducted by patients, rhinorrhea significantly ameliorated
in the first study while in the second study a significant
reduction for bleeding, cacosmia, and exudate viscosity was
also observed. Efficacy and tolerability were judged “good” by
physicians and patients in both treatments.
3.4. Ectoine and Acute Pharyngitis and/or Laryngitis. Müller
D et al. [14] compared the effects of ectoine oral spray
to saline lozenges in the treatment of acute pharyngitis
and/or laryngitis in 95 patients for 7 days. In particular, 64
patients received ectoine oral spray (one to two puffs several
times a day) while 31 patients received lozenges (one to
two lozenges up to six times a day). At all follow-up visits,
physicians and patients evaluated hoarseness, swallowing
difficulties, pharyngitis symptom score, tolerability, efficacy,
and adverse events. At the end of the treatment, ectoine
oral spray guaranteed an earlier improvement of hoarseness,
swallowing difficulties, and pharyngitis symptom score than
control group without statistical differences. Treatment with
ectoine oral spray showed higher efficacy than control group,
as judged by physicians and patients recording a statistical
significance only in the patient’s evaluation. Both physicians
and patients rated the tolerability of the spray and the
lozenges as “good” to “very good.” No serious adverse effects
have been reported.
Dao VA et al. [15] enrolled 90 patients with acute
pharyngitis: 35 patients using ectoine (1-2 lozenges every
3 h or as needed), 35 patients with hyaluronic acid (one
or two lozenges every 2-3 hands up to six times daily if
necessary), and 20 patients with hypertonic saline gargle (3-
5 times daily). All treatment lasted 7 days. Physicians and
patients assessed primary variables (pain on swallowing, urge
to cough, and hoarseness), secondary variables (dry mouth
and throat, reddening of the oropharynx, reddening of the
larynx, burning sensation in the throat, and patient’s general
health condition), effectiveness, tolerability, and compliance.
At the end of the treatment, primary variables significantly
decreased in all three groups from baseline. The reduc-
tions were significantly greater in ectoine and hyaluronic
acid groups than saline gargle group. Regarding individ-
ual symptoms evaluated by physicians ectoine was more
effective than hyaluronic acid in ameliorating the symptom
of reddening of the larynx. Investigators and the patients
confirmed that ectoine was significantly more effective than
saline gargle in improving general health condition, but
hyaluronic acid was not. Effectiveness evaluation conducted
by physicians and patients showed a greater improvement
in ectoine and hyaluronic acid groups than saline gargle
group. The tolerability of ectoine was better than hyaluronic
acid reaching significance only in the physicians’ evaluation.
Physicians’ assessment of compliance showed significantly
better value in ectoine group than hyaluronic acid group
while patients’ evaluation only highlighted that both lozenges
were significantly better than the saline gargle.
4. Discussion
Medical management of sinonasal and oral inflammatory
diseases increasingly involves the use of topical agents, which
BioMed Research International 9








dehydration and greater sensitivity
to external agents
Mediator of inflammation
Figure 1: Ectoine’s mechanism of action. Influence of water molecules alone (on the left) and aqueous solution of ectoine (on the right) on
lipid bilayer.
offer an improved ability to deliver high concentrations of
drugs to the UA mucosa avoiding systemic effects. Given
the pivotal role that topical therapies play in many sinonasal
and oral conditions, considerable interest in the effectiveness,
tolerability, and compliance of specific new substances has
become evident [16]. Literature data that emerged from our
analysis allow us to affirm that topical administration of
ectoine can be useful as coadjutant treatment in the acute
and chronic inflammatory diseases of UA such as AR, ARS,
rhinitis sicca, pharyngitis, and laryngitis. Ectoine is natural
amino acid derivate produced by bacteria living under
extreme environment conditions acting as osmoregulatory
compatible solute. The stabilizations effects on the barrier
function of the epithelial tissue have led to the hypothesis
that ectoine increases the resistance of the UA mucosa and
improves its recovery (Figure 1). Thanks to the “preferential
hydration,” ectoine reduces nasal symptoms of patients with
rhinitis sicca increasing the fluidity of the nasal epithelia and
inhibiting the potential loss of water [13]. Topical ectoine
has proved effective also for the most common inflam-
matory conditions of the pharynx and larynx, improving
both the patients’ diary data and the physical examinations,
supporting a potential therapeutic role of ectoine on all the
upper aerodigestive tract [14, 15]. In addition, Sonnemann
U et al. [10] suggested ectoine nasal sprays as interesting
alternative treatment strategies for symptom reduction in
AR patients, particularly for those seeking nonpharmaceu-
tical treatments, as they contain a natural substance and
are free of preservatives. Ectoine could play a key role in
allergic disease of the upper and lower airway reducing the
exacerbation of the immune response in antigen-exposed
sensitized individuals and allergic sensitization against daily
life. In particular, it has been shown that ectoine effect on
the exacerbation of the immune response is not due to an
interaction with the external particles, which might reduce
the reactive surface area and thereby diminish the proinflam-
matory effects. Instead, prevention of carbon nanoparticles
induced lung inflammation represents an ectoine-dependent
reaction of the organism thought a mechanism involving
the stabilization of macromolecules located at the outer cell
surface. This hypothesis is further supported by the finding
that ectoine is able to reduce pathogenic endpoints in skin
epithelial cells induced by solar UVA radiation as a source for
physical stress due to a stabilization of lipid microdomains
(rafts) in the cytoplasm membrane and a decrease in UVA-
induced ceramide release in human keratinocytes [17–19].
It has also been shown that ectoine can reduce the allergic
sensitization. In particular, carbon nanoparticles seem to
enhance the migration of antigen loaded dendritic cells to
the draining lymph nodes and ectoine appears to prevent
this effect either via direct action on dendritic cells or
via the suppression of the neutrophilic inflammation [20].
All these mechanisms might stabilize mucous membranes
improving the epithelial barrier such as lining epithelia of the
nose, thereby protecting those from invading allergens and
reducing allergen-induced inflammations.
In all the trials analyzed, spray represents the most
common device used and no serious adverse effects and con-
traindications have been reported. The clinical trials lasted
between seven and fourteen days and ectoine nasal sprays
have been used with a very different treatment frequency
(from three to several times a day).
There are some lines of evidence that topically admin-
istered ectoine improves the global subjective and clinical
10 BioMed Research International
status of patients affected by UA inflammatory diseases,
even if these findings should be viewed cautiously as they
are based on a limited number of studies, some of which
were probably underpowered because of their small patient
samples. Further researches should be performed in order
to confirm the effectiveness of topical administered ectoine
in such patients, to define the better therapeutic protocols
(way of administration and dosage) and to selectively test
its effectiveness in the paediatric age. The strong connection
between particle diameter and site of the high concentration
of nebulized particles in the UA suggests that it should be also
mandatory to carefully choose the “ideal” nebulizer device to
get better therapeutic results [21].
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